The Food and Drug Administration (FDA) has put four companies on notice for marketing “unapproved fluoride-containing ingestible drugs” for use by children under the age of 3 or children at low or ...

Texas voters approved a $20 billion infrastructure fund that could increase demand for plastic piping in water, wastewater ...

The US Food and Drug Administration said Friday that it is taking action to restrict the use of prescription fluoride supplements, following a directive from the government’s Make American Healthy ...

The Food and Drug Administration is restricting the use of fluoride supplements used to strengthen children’s teeth ...

The IDE approval marks a pivotal milestone for Aqua Medical, allowing the company to begin enrolling patients in the U.S. RESTORE-1 pilot trial and study PIMA's potential to deliver durable metabolic ...

The updated indications state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy. The Food ...

New Mexico’s ‘Free’ Child Care an Attempt to Cover for Past Failures The Virtue of Liberty: A Response to the NatCons Trump Administration Says Drug-Boat Strikes Are Not Really ‘Hostilities,’ as Death ...

Aqua Medical has received investigational device exemption (IDE) from the FDA for its ablation device aimed at treating ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...

The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of the multiple myeloma treatment could increase the risk of an intestinal ...

Xspray Pharma has taken hit after hit during its repeated efforts to commercialize its leukemia prospect Dasynoc. On its third attempt to win the FDA’s favor, the company has run into yet another ...